NeuroSense Therapeutics Ltd. (NRSN) Form 6-K — Oct 19, 2026
NeuroSense Therapeutics filed a U.S. patent application covering the use of PrimeC (ciprofloxacin plus celecoxib) to treat traumatic brain injury, including concussion, blast-related injury and chronic traumatic encephalopathy. If granted, the patent is expected to provide protection through 2047. TBI affects millions worldwide and currently has no approved disease-modifying therapy, so the filing positions PrimeC for potential expansion beyond ALS, supporting future research partnerships and non-dilutive funding opportunities.
Key figures
- Als annual diagnoses us
- 5,000+
- Patent protection through
- 2047
- Als patients growth by 2040
- 24% in U.S. and EU
- Als annual disease burden usd
- $1 billion
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.